XML 19 R10.htm IDEA: XBRL DOCUMENT

Other Current Assets	3 Months Ended
Mar. 31, 2024
Other Current Assets:
Other Current Assets	4. Other Current Assets As of March 31, 2024, other current assets included prepaid expenses of $0.8 million, comprised primarily of prepayments of $0.5 million made for the Company’s clinical trial for BP1001-A in solid tumors. Additionally, the Company had prepaid expenses related to its insurance policies of $0.1 million, preclinical studies of $0.1 million and other prepaid expenses of $0.1 million. As of December 31, 2023, other current assets included prepaid expenses of $1.4 million, comprised primarily of prepayments of $0.9 million made for the Company’s clinical trials for BP1002 in AML and lymphoma and BP1001-A in solid tumors as well as prepaid insurance of $0.3 million, prepaid Delaware franchise tax of $0.1 million and other prepaid expenses of $0.1 million.

Other Current Assets

3 Months Ended

Mar. 31, 2024

4. Other Current Assets

As of March 31, 2024, other current assets included prepaid expenses of $0.8 million, comprised primarily of prepayments of $0.5 million made for the Company’s clinical trial for BP1001-A in solid tumors. Additionally, the Company had prepaid expenses related to its insurance policies of $0.1 million, preclinical studies of $0.1 million and other prepaid expenses of $0.1 million. As of December 31, 2023, other current assets included prepaid expenses of $1.4 million, comprised primarily of prepayments of $0.9 million made for the Company’s clinical trials for BP1002 in AML and lymphoma and BP1001-A in solid tumors as well as prepaid insurance of $0.3 million, prepaid Delaware franchise tax of $0.1 million and other prepaid expenses of $0.1 million.